Fred A Dijcks (Fred Dijcks)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 3

Top Topics

Endoplasmic Reticulum Stress

Top Venues

Cancer research

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Patrick G Groothuis, Daniëlle C H Jacobs, Inge A T Hermens, Désirée Damming, Kim Berentsen, Ellen Mattaar-Hepp, Marloes E M Stokman, Tinie Van Boekel, Myrthe Rouwette, Monique A J Van der Vleuten, Aloys Sesink, Fred A Dijcks, Ruud G E Coumans, Jan Schouten, Dirk H Glaudemans, Daniëlle van Wijk, Marion Blomenröhr, Wendela A Kappers, Ruud Ubink, Miranda M C Van der Lee, Wim H A Dokter
Preclinical profile of BYON3521 predicts an effective and safe c-MET-antibody-drug conjugate. Molecular cancer therapeutics (2023)
Santiago Duro-Sánchez, Mercedes Nadal-Serrano, Marta Lalinde-Gutiérrez, Enrique J Arenas Lahuerta, Cristina Bernadó Bernadó Morales, Beatriz Morancho, Marta Escorihuela, Sandra Pérez-Ramos, Santiago Escriva-de-Romani, Lucía Gandullo-Sánchez, Atanasio Pandiella, Anna Esteve-Codina, Veronica Rodilla, Fred A Dijcks, Wim H A Dokter, Javier Cortes, Cristina Saura, Joaquín Arribas
Therapy-induced senescence enhances the efficacy of HER2-targeted antibody-drug conjugates in breast cancer. Cancer research (2022)
Patrick Groothuis, Nicolas Penel, Antoine Italiano, Nuria Kotecki, Fred A Dijcks, Wim Dokter
High Prevalence of 5T4/Trophoblast Glycoprotein in Soft Tissue Sarcomas. Cancers 13 (19) (2021)